Mucormycosis
18
2
4
10
Key Insights
Highlights
Success Rate
100% trial completion (above average)
Clinical Risk Assessment
Based on trial outcomes
Moderate Risk
Score: 50/100
0.0%
0 terminated out of 18 trials
100.0%
+13.5% vs benchmark
0%
0 trials in Phase 3/4
20%
2 of 10 completed with results
Key Signals
Data Visualizations
Phase Distribution
Trial Status
Trial Success Rate
Benchmark: 86.5%
Based on 10 completed trials
Clinical Trials (18)
Post Marketing Surveillance (PMS) Study of Cresemba in Korea.
Disease Burden Transition of Mucormycosis in Hematologic Malignancies Population Across Covid 19 Era: a Single-center Comparative Analysis From China
Biomarkers for Invasive Mucormycosis
A Study to Understand How the Use of Paxlovid Affected the Healthcare Use in People With Pre-existing Conditions.
Amphotericin B Versus Isavuconazole for Mucormycosis: A Comparative Efficacy and Safety Study
Mucormycosis Clinical Core for the MUCOR-ADVANCE P01 Project
Isavuconazole in Critically Ill Patients: Efficacy and Safety
Study on Theraputic Drug Monitoring and Phamacokinetics of Isavuconazole in Children
Rehabilitation With an Obturator in Maxillary Defects
Mucorales PCR Screening in At-risk Hematology Patients
COVID-19 and Rhino-orbital Mucormycosis
The Deferasirox-AmBisome Therapy for Mucormycosis (DEFEAT Mucor) Study
Mucormycosis in COVID-19
Mucormycosis in ICU
Evaluation of Using 3D Printed PEEK Facial Implants in Repairing Maxillofacial Deformities
Ocular Manifestation and Related Risk Factors of Covid-19 Associated Mucormycosis: a Multicenter Study in Iran
COVID-19 Associated Mucormycosis: A Multidisciplinary Dilemma in Assiut University Hospital
Prospective Evaluation of a New Molecular Tool for Early Diagnosis of Mucormycosis